SK288048B6 - Use of a substance effective in modulating signal transduction mediated by AILIM for suppressing, treating or preventing graft rejection and pharmaceutical composition comprising the substance for use in suppressing, treating or preventing graft rejection - Google Patents
Use of a substance effective in modulating signal transduction mediated by AILIM for suppressing, treating or preventing graft rejection and pharmaceutical composition comprising the substance for use in suppressing, treating or preventing graft rejection Download PDFInfo
- Publication number
- SK288048B6 SK288048B6 SK1214-2003A SK12142003A SK288048B6 SK 288048 B6 SK288048 B6 SK 288048B6 SK 12142003 A SK12142003 A SK 12142003A SK 288048 B6 SK288048 B6 SK 288048B6
- Authority
- SK
- Slovakia
- Prior art keywords
- ailim
- antibody
- polypeptide
- heart
- binds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Graft Or Block Polymers (AREA)
- External Artificial Organs (AREA)
- Transplanting Machines (AREA)
- Soil Working Implements (AREA)
- Cylinder Crankcases Of Internal Combustion Engines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001056209 | 2001-03-01 | ||
| JP2001056216 | 2001-03-01 | ||
| JP2002008028 | 2002-01-16 | ||
| PCT/JP2002/000930 WO2002070010A1 (fr) | 2001-03-01 | 2002-02-05 | Inhibiteurs de rejet du greffon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK12142003A3 SK12142003A3 (sk) | 2004-05-04 |
| SK288048B6 true SK288048B6 (sk) | 2013-03-01 |
Family
ID=27346134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1214-2003A SK288048B6 (sk) | 2001-03-01 | 2002-02-05 | Use of a substance effective in modulating signal transduction mediated by AILIM for suppressing, treating or preventing graft rejection and pharmaceutical composition comprising the substance for use in suppressing, treating or preventing graft rejection |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7438905B2 (fr) |
| EP (2) | EP1769807B1 (fr) |
| JP (1) | JP4212278B2 (fr) |
| KR (1) | KR100609444B1 (fr) |
| CN (1) | CN1518458B (fr) |
| AT (2) | ATE463256T1 (fr) |
| AU (1) | AU2002228435B2 (fr) |
| BR (1) | BR0207787A (fr) |
| CA (1) | CA2439858C (fr) |
| CY (1) | CY1110143T1 (fr) |
| CZ (1) | CZ20032406A3 (fr) |
| DE (2) | DE60235928D1 (fr) |
| DK (1) | DK1769807T3 (fr) |
| ES (1) | ES2344219T3 (fr) |
| HK (2) | HK1061531A1 (fr) |
| HU (2) | HU228045B1 (fr) |
| IL (2) | IL156845A0 (fr) |
| MX (1) | MXPA03006736A (fr) |
| NO (2) | NO331690B1 (fr) |
| NZ (1) | NZ527076A (fr) |
| PT (1) | PT1769807E (fr) |
| RU (1) | RU2263512C2 (fr) |
| SI (1) | SI1769807T1 (fr) |
| SK (1) | SK288048B6 (fr) |
| WO (1) | WO2002070010A1 (fr) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| CN1411373A (zh) * | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| JP2006321765A (ja) * | 2005-05-20 | 2006-11-30 | Mikiko Ueda | 肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬 |
| CN101861168B (zh) * | 2007-05-07 | 2014-07-02 | 米迪缪尼有限公司 | 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用 |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| EP2455396A4 (fr) * | 2009-07-16 | 2013-05-01 | Otsuka Chemical Co Ltd | Domaine extracellulaire ailim à chaîne de sucre ajoutée et son procédé de production |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| WO2011130322A1 (fr) * | 2010-04-12 | 2011-10-20 | University Of Miami | Échafaudages biotechnologiques macroporeux pour la transplantation de cellules |
| RU2456615C1 (ru) * | 2011-03-25 | 2012-07-20 | Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации | Способ профилактики отторжения трансплантата трупной почки |
| WO2012131004A2 (fr) * | 2011-03-31 | 2012-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps dirigés contre icos et utilisation de ceux-ci |
| US20150139994A1 (en) * | 2013-11-12 | 2015-05-21 | The Regents Of The University Of California | Compositions and methods for preventing allogeneic immune rejection |
| ME03318B (fr) * | 2013-11-22 | 2019-10-20 | Shire Viropharma Inc | Méthodes de traitement de rejet médié par les anticorps chez des patients transplantés à l'aide d'un inhibiteur de c1-estérase |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| ES2824108T3 (es) | 2014-03-12 | 2021-05-11 | Icahn School Med Mount Sinai | Método para identificar receptores de aloinjertos de riñón en riesgo de lesión crónica |
| US10308985B2 (en) | 2014-06-26 | 2019-06-04 | Icahn School Of Medicine At Mount Sinai | Methods for diagnosing risk of renal allograft fibrosis and rejection |
| EP3161165B1 (fr) | 2014-06-26 | 2020-11-18 | Icahn School of Medicine at Mount Sinai | Procédé permettant de diagnostiquer une forme infraclinique et clinique du rejet aigu par analyse de séries de gènes prédictifs, agents therapeutiques pour le traitement et jeux pour determiner l'expression |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3366691A1 (fr) | 2015-12-03 | 2018-08-29 | GlaxoSmithKline Intellectual Property Development Limited | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
| WO2017098421A1 (fr) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Composés benzothiadiazine |
| WO2017153952A1 (fr) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de 5-sulfamoyl-2-hydroxybenzamide |
| CA3019628A1 (fr) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Amides heterocycliques utiles en tant que modulateurs de proteine |
| KR102527786B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
| JP2019516685A (ja) | 2016-05-05 | 2019-06-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２阻害剤のエンハンサー |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3471753A1 (fr) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 et cytokines il-2 |
| WO2018029474A2 (fr) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anticorps anti-icos |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| CN116640214A (zh) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
| CN110573504A (zh) | 2017-02-27 | 2019-12-13 | 葛兰素史克知识产权开发有限公司 | 作为激酶抑制剂的杂环酰胺 |
| JP2020522555A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組み合わせ療法 |
| BR112019025913A2 (pt) | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
| BR112019025257A2 (pt) | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019021208A1 (fr) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Dérivés d'indazole utiles en tant qu'inhibiteurs de perk |
| WO2019053617A1 (fr) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
| JP2020533380A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌の組合せ治療 |
| TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| WO2019069270A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des gènes (sting) de l'interféron |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (fr) | 2017-12-19 | 2020-10-28 | Kymab Limited | Anticorps bispécifique pour icos et pd-l1 |
| RU2688172C1 (ru) * | 2018-04-05 | 2019-05-20 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ профилактики отторжения трансплантата трупной почки |
| JP7464279B2 (ja) | 2018-04-16 | 2024-04-09 | アイカーン スクール オブ メディスン アット マウント シナイ | レシピエント血液における移植前トランスクリプトームシグネチャーを使用した急性拒絶反応および腎臓同種異系移植喪失の予測のための方法およびキット |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CA3101553A1 (fr) | 2018-05-31 | 2019-12-05 | Glaxosmithkline Intellectual Property Development Limited | Association d'un inhibiteur des proteine arginine methyltransferases de type ii et d'une proteine se liant a icos pour traiter le cancer |
| WO2019229613A1 (fr) | 2018-05-31 | 2019-12-05 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie avec des protéines de liaison à icos et des inhibiteurs d'arginine méthyltransférase |
| WO2020031087A1 (fr) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie |
| BR112021007517A2 (pt) | 2018-10-22 | 2021-10-26 | Glaxosmithkline Intellectual Property Development Limited | Dosagem |
| US20200368369A1 (en) * | 2019-05-22 | 2020-11-26 | Wyvern Pharmaceuticals Inc. | Composition for endogenous production of checkpoint protein precursors |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (fr) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Méthodes de traitement du cancer |
| WO2021043961A1 (fr) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et une chimiothérapie |
| WO2021046293A1 (fr) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et du trémélimumab |
| EP4034562A2 (fr) | 2019-09-27 | 2022-08-03 | GlaxoSmithKline Intellectual Property Development Limited | Protéines de liaison à un antigène |
| CN113294813B (zh) * | 2020-02-24 | 2022-09-02 | 宁波方太厨具有限公司 | 一种电磁灶 |
| CN115397861A (zh) | 2020-04-14 | 2022-11-25 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| CA3171557A1 (fr) | 2020-04-14 | 2021-10-21 | Marc S. BALLAS | Traitement combine pour le cancer impliquant des anticorps anti-icos et anti-pd1, impliquant eventuellement en outre des anticorps anti-tim3 |
| CN115461362A (zh) | 2020-04-14 | 2022-12-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| BR112023017296A2 (pt) | 2021-03-02 | 2023-11-14 | Glaxosmithkline Ip Dev Ltd | Piridinas substituídas como inibidores de dnmt1 |
| EP4314060A1 (fr) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Protéines de liaison à l'antigène et leurs combinaisons |
| CA3219336A1 (fr) | 2021-05-18 | 2022-11-24 | Kymab Limited | Utilisations d'anticorps anti-icos |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023222854A1 (fr) | 2022-05-18 | 2023-11-23 | Kymab Limited | Utilisations d'anticorps anti-icos |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
| US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| JP4864175B2 (ja) | 1996-01-23 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 発作に関する抗―ｃｄ１８抗体 |
| US5914112A (en) | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| CN1151838C (zh) | 1996-09-18 | 2004-06-02 | 泽特希斯有限公司 | 作为抗自身免疫疾病试剂的蛋白的用途 |
| JP4048294B2 (ja) * | 1996-11-08 | 2008-02-20 | バイオジェン・アイデック・インコーポレイテッド | ある種の抗体とヒトｂ７．１およびｂ７．２コスティミュラトリー抗原との間の独特の結合相互作用の同定 |
| WO1998037415A1 (fr) | 1997-02-20 | 1998-08-27 | The Regents Of The University Of California | ANTIGENE DE LA VESICULE SECRETRICE DE pANCA DE LA RECTO-COLITE HEMORRAGIQUE |
| FI107538B (fi) * | 1997-02-26 | 2001-08-31 | Raisio Benecol Oy | Menetelmä stanoliesterien valmistamiseksi |
| US7112655B1 (en) * | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| WO2001018022A1 (fr) | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | 52 proteines humaines secretees |
| DK0973804T3 (da) | 1997-04-07 | 2007-05-07 | Genentech Inc | Anti-VEGF-antistoffer |
| US7259247B1 (en) * | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| JPH11228442A (ja) * | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
| JP2000154151A (ja) * | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
| AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| CA2346496A1 (fr) | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | Nouvelles molecules specifiques de th2 et leurs utilisations |
| DK2332976T3 (da) * | 1999-02-03 | 2014-06-23 | Amgen Inc | Nye polypeptider, der er involveret ved et immunrespons |
| JP2002544170A (ja) | 1999-05-06 | 2002-12-24 | ジェネティックス・インスチチュート・インコーポレーテッド | 免疫応答を高めるための可溶性同時刺激分子の使用 |
| US6613327B1 (en) | 1999-07-28 | 2003-09-02 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
| WO2001012658A2 (fr) | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Acides nucleiques, polypeptides, analyses, moyens et techniques therapeutiques |
| JP3871503B2 (ja) * | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| WO2001021796A2 (fr) | 1999-09-21 | 2001-03-29 | Genetics Institute, Inc. | Molecules gl50 et leurs utilisations |
| AU1342501A (en) | 1999-10-29 | 2001-05-14 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| WO2001064704A1 (fr) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | LA hB7-H2, NOUVELLE MOLECULE CO-STIMULANTE |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| ES2536653T3 (es) | 2000-11-28 | 2015-05-27 | Amgen Inc. | Polipéptidos implicados en la respuesta inmunitaria |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
2002
- 2002-01-22 JP JP2002013189A patent/JP4212278B2/ja not_active Expired - Fee Related
- 2002-02-05 RU RU2003129166/15A patent/RU2263512C2/ru not_active IP Right Cessation
- 2002-02-05 MX MXPA03006736A patent/MXPA03006736A/es active IP Right Grant
- 2002-02-05 PT PT06024523T patent/PT1769807E/pt unknown
- 2002-02-05 ES ES06024523T patent/ES2344219T3/es not_active Expired - Lifetime
- 2002-02-05 DE DE60235928T patent/DE60235928D1/de not_active Expired - Lifetime
- 2002-02-05 CZ CZ20032406A patent/CZ20032406A3/cs unknown
- 2002-02-05 AT AT06024523T patent/ATE463256T1/de active
- 2002-02-05 CA CA002439858A patent/CA2439858C/fr not_active Expired - Fee Related
- 2002-02-05 AU AU2002228435A patent/AU2002228435B2/en not_active Ceased
- 2002-02-05 EP EP06024523A patent/EP1769807B1/fr not_active Expired - Lifetime
- 2002-02-05 HU HU0303332A patent/HU228045B1/hu not_active IP Right Cessation
- 2002-02-05 SK SK1214-2003A patent/SK288048B6/sk not_active IP Right Cessation
- 2002-02-05 DE DE60217839T patent/DE60217839T2/de not_active Expired - Lifetime
- 2002-02-05 EP EP02710508A patent/EP1374901B9/fr not_active Expired - Lifetime
- 2002-02-05 AT AT02710508T patent/ATE352318T1/de not_active IP Right Cessation
- 2002-02-05 SI SI200230901T patent/SI1769807T1/sl unknown
- 2002-02-05 NZ NZ527076A patent/NZ527076A/xx not_active IP Right Cessation
- 2002-02-05 CN CN028058054A patent/CN1518458B/zh not_active Expired - Fee Related
- 2002-02-05 IL IL15684502A patent/IL156845A0/xx active IP Right Grant
- 2002-02-05 BR BR0207787-6A patent/BR0207787A/pt not_active IP Right Cessation
- 2002-02-05 KR KR1020037011255A patent/KR100609444B1/ko not_active IP Right Cessation
- 2002-02-05 WO PCT/JP2002/000930 patent/WO2002070010A1/fr active IP Right Grant
- 2002-02-05 DK DK06024523.0T patent/DK1769807T3/da active
- 2002-02-05 HU HU1100018A patent/HU228108B1/hu not_active IP Right Cessation
-
2003
- 2003-07-09 IL IL156845A patent/IL156845A/en not_active IP Right Cessation
- 2003-08-29 NO NO20033839A patent/NO331690B1/no not_active IP Right Cessation
-
2004
- 2004-03-04 US US10/793,171 patent/US7438905B2/en not_active Expired - Fee Related
- 2004-06-24 HK HK04104524A patent/HK1061531A1/xx not_active IP Right Cessation
-
2007
- 2007-09-27 HK HK07110465.8A patent/HK1102293A1/xx not_active IP Right Cessation
-
2008
- 2008-09-12 US US12/209,643 patent/US20090047292A1/en not_active Abandoned
-
2010
- 2010-06-04 CY CY20101100496T patent/CY1110143T1/el unknown
-
2011
- 2011-02-08 NO NO20110218A patent/NO20110218L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7438905B2 (en) | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM | |
| KR100609441B1 (ko) | 면역성 질환 치료제 | |
| KR100602940B1 (ko) | 염증성 장질환 치료제 | |
| EP2040730B1 (fr) | Modulation du nkg2d chez des patients infectes par hbv | |
| ZA200306516B (en) | Graft rejection inhibitors. | |
| JP3543966B2 (ja) | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 | |
| JP2004261182A (ja) | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20150205 |